CatalystFDA/Bio

ARROWHEAD’S PLOZASIRAN CUTS PANCREATITIS EVENTS IN PHASE 3 STUDIES - SEEKINGALPHA

Phase 3 data shows plozasiran reduced pancreatitis events, a key efficacy catalyst.

What changed

Why it matters

Phase 3 data shows plozasiran reduced pancreatitis events, a key efficacy catalyst.

Sources